Humacyte (HUMA)
Commercializing Symvess while expanding its ATEV vessel platform.
Something off on this page? Send us feedback.
Sells Symvess for urgent vascular trauma and develops ATEV tissue vessels for dialysis access and other vascular uses. Revenue is concentrated in Symvess, with uptake shaped by trauma-center adoption, reimbursement, safety monitoring, and access to capital.
Commercializes Symvess, an acellular tissue engineered vessel for adults with extremity arterial injury when urgent revascularization is needed and autologous vein graft is not feasible. The same ATEV platform is being developed for dialysis access, PAD, CABG, pediatric heart surgery, and other tissue or cell-delivery uses.
Operates from Durham under consolidated segment reporting and a manufacturing-led model. U.S. launch work is focused on trauma centers, hospital value-analysis adoption, surgeon demand, reimbursement, and VA access.
Executes around founder-scientist continuity and scaled production of off-the-shelf human tissues. The business depends on Symvess uptake, additional indications, FDA postmarketing safety work around graft failure and infection, and continued access to capital.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 12, 2026 | BTIG | Reiterate | Rating: —Target: $10 | Target: $2 |
| Dec 1, 2025 | H.C. Wainwright | Target | Target: — | Target: $3 |
| Oct 13, 2025 | UBS | Target | Target: — | Target: $6 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $79.9M · Total debt $66.2M · Total assets $138.1M · Shareholders' equity $31.3M
- Revenue
- $406.0K
- Operating income
- −$27.0M
- Net income
- −$36.8M
No dividends on record.
| Institutions | 26.90% | 74.74M shares | |
|---|---|---|---|
| 174 holders · as of Jun 30, 2026 | |||
| Insiders | 0.39% | 1.10M shares | |
| 8 holders · as of Sep 15, 2026 | |||
| Other | 72.71% | 201.96M shares | |
| remainder | |||
277.80M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (277.80M in the company's Sep 23, 2026 report, 168.00M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Vanguard Capital Management LLCInstitution | 3.64% | 10.11M | as of Jun 30, 2026 |
Antipodes Partners LtdInstitution | 3.64% | 10.10M | as of Jun 30, 2026 |
Alyeska Investment Group, L.P.Institution | 2.17% | 6.02M | as of Jun 30, 2026 |
Davidson Kempner Capital Management LPInstitution | 1.80% | 5.00M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 1.74% | 4.84M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 14, 2026 | Keith Anthony Jones | director | +10,000 | $0.5620 |
| Aug 20, 2026 | Keith Anthony Jones | director | +10,000 | $0.6930 |
| Aug 17, 2026 | Keith Anthony Jones | director | +30,000 | $0.5940 |
| May 18, 2026 | Shamik J. Parikh | officer: Chief Medical Officer | −45,887 | $0.8967 |
| May 18, 2026 | Dale A. Sander | officer: CFO and Chief Corp. Dev. Off | −45,887 | $0.8967 |
